Chronic Lymphocytic Leukemia | Specialty

Dr. Farrukh Awan Explains Syk Inhibitor in CLL

February 24th 2016

Farrukh Awan, MBBS, assistant professor of internal medicine, Ohio State University, discusses the role for spleen tyrosine kinase (Syk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL).

Blinatumomab Nears 70% Response Rate in Non-Hodgkin Lymphoma

February 18th 2016

The anti-CD19 agent blinatumomab (Blincyto) induced a response rate of 69% in patients with non-Hodgkin Lymphoma.

SYK Inhibitor Shows Promise in CLL

February 18th 2016

Entospletinib (GS-9973) has shown early promise as a treatment for pretreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

January 28th 2016

Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLL

January 25th 2016

Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.

FDA Grants Venetoclax Combination Breakthrough Designation in CLL

January 21st 2016

Venetoclax has received an FDA breakthrough therapy designation for use in combination with rituximab to treat patients with relapsed/refractory chronic lymphocytic leukemia.

Maintenance Ofatumumab Approved in CLL

January 19th 2016

FDA Approves Maintenance Ofatumumab in CLL

January 19th 2016

The FDA has approved ofatumumab (Arzerra) for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial response following at least two lines of therapy.

Emerging Chronic Lymphocytic Leukemia Therapies

January 19th 2016

Venetoclax in Chronic Lymphocytic Leukemia

January 19th 2016

Evaluating the Role of Idelalisib in CLL

January 19th 2016

Mechanisms of Ibrutinib Resistance in CLL

January 19th 2016

Pharmacovigilance with Ibrutinib in CLL

January 19th 2016

Using Ibrutinib in Chronic Lymphocytic Leukemia

January 19th 2016

Small-Molecule Inhibitors: Ibrutinib in CLL

January 19th 2016

The Role of Ofatumumab in the Treatment of CLL

January 19th 2016

CD-20 Antibodies in Chronic Lymphocytic Leukemia

January 19th 2016

Chemoimmunotherapy in Chronic Lymphocytic Leukemia

January 19th 2016

The Value of CT Scans in Chronic Lymphocytic Leukemia

January 19th 2016